-->

Company Registry

Nabla Bio Inc
Profile last edited on: 2/11/2022

Autoverse platform of proprietary biologically informed machine-learning co-developing antibody drugs
Year Founded
2020
First SBIR Year
2021
Latest SBIR Award
2021
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

127 Western Avenue
Boston, MA 02134
   (919) 757-1609
   N/A
   www.nabla.bio
Multiple Locations:   
Congressional District:   07
County:   Suffolk

Public Profile

A spin-out from Harvard, Nabla Bio is structured around development of novel proteins intended for medical and industrial applications. Applying AI technology to antibody design, the company's supernatural proteins are extrapolated from insights learned from billions of natural ones and are enhanced through diverse protein variants through numerous experiments, enabling clients to carry out implementations involving complex measurements of protein function. Inidcating that the next generation of antibodies will be designed rather than discovered, and these designs will be aided by artificial intelligence.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2021 1 NSF $256,000
Highly resource-efficient protein engineering using machine learning

Key People / Management

  Frances Anastassacos -- Co-Founder

  Surojit (Surge) Biswas --

SBIR firms in the news

There are no news available.